Fact CheckerSign in

NCT04553692CompletedPhase 1

AN OPEN-LABEL, MULTICENTER, PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED, REFRACTORY, OR NEWLY DIAGNOSED CANCERS

Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Sept 2024

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
22 (actual)
First submitted
12 Jul 2023
Start date
23 Nov 2023
Lead sponsor
IGM Biosciences Inc.
NCT number
NCT04553692
EU CT number
2023-504545-31-00

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 22
  • 10 sites in 2 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.

Sites (10)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hospital Universitari Vall d'Hebron
Coordinator of this site? Confirm its status
BarcelonaSpainCompleted
Hospital Universitario HM Sanchinarro
Coordinator of this site? Confirm its status
MadridSpainCompleted
Clinica Universidad de Navarra
Coordinator of this site? Confirm its status
MadridSpainCompleted
Hospital Universitario Fundación Jiménez Díaz
Coordinator of this site? Confirm its status
MadridSpainCompleted
Clínica Universidad de navarra
Coordinator of this site? Confirm its status
PamplonaSpainCompleted
Institut Bergonie
Coordinator of this site? Confirm its status
BordeauxFranceCompleted
Centr Georges Francois Leclerc
Coordinator of this site? Confirm its status
DijonFranceCompleted
Hopital Saint Louis
Coordinator of this site? Confirm its status
ParisFranceCompleted
Institut De Cancerologie De L Ouest
Coordinator of this site? Confirm its status
St HerblainFranceCompleted
Institut Gustave Roussy
Coordinator of this site? Confirm its status
VillejuifFranceCompleted

This page is information, not medical advice. Discuss any trial with your doctor.